Navelbine (Vinorelbine)

Vinorelbine belongs to the Vinca alkaloid class and binds to the β‑tubulin component of microtubules. By preventing microtubule polymerisation, it blocks mitotic spindle formation, causing cell‑cycle arrest at metaphase and triggering apoptosis of rapidly dividing cancer cells.

The dose of Navelbine is individualized by the prescribing oncologist based on factors such as the type of cancer, treatment protocol, patient weight, renal and hepatic function, and prior therapy. Only a qualified healthcare professional should determine the appropriate regimen.

The safety of vinorelbine during pregnancy and lactation has not been established. Because it may cause fetal harm, it is generally contraindicated in pregnant women, and breastfeeding is not recommended while receiving treatment.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Navelbine. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Vinorelbine offers a distinct mechanism by targeting microtubule assembly, which can be advantageous in tumors resistant to taxanes. Compared with agents such as paclitaxel, vinorelbine may have a different toxicity profile, often showing lower rates of peripheral neuropathy but higher incidences of neutropenia. Choice of therapy depends on individual patient factors and oncologist judgment.

Navelbine capsules should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Navelbine is administered orally in capsule form. The capsules are swallowed whole with water, usually on an empty stomach or as directed by the treating physician. Administration timing and any required pre‑medication are determined by the oncologist based on the treatment protocol.

The most serious adverse events include severe neutropenia with fever (febrile neutropenia), pulmonary toxicity such as interstitial pneumonitis or fibrosis, and peripheral neuropathy. Patients should be monitored closely for signs of infection, respiratory symptoms, and neurological changes, and any concerning signs should prompt immediate medical evaluation.

Vinorelbine is contraindicated in patients with known hypersensitivity to the drug or other Vinca alkaloids. It should also be avoided in individuals with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment unless dose adjustments are made. Pregnant or breastfeeding women should not receive the medication.